The investor presentation “MagSense® Technology: A New Diagnostic for Targeted Early Detection of Cancer” was presented at the 2017 Annual General Meeting. View the Investor Presentation.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal